TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Bristol-Myers Squibb ( (BMY) ) is now available.
On November 17, 2025, Bristol-Myers Squibb announced the early participation results and amendments to its cash tender offers to purchase outstanding notes. The company adjusted the maximum purchase amounts for its Pool 1 and Pool 2 Notes and confirmed that all validly tendered notes before the deadline will be accepted without proration, except for the 2033 Notes, which will be prorated. The early settlement is set for November 20, 2025, and no further tenders will be accepted after the early deadline, as the maximum thresholds have been met.
The most recent analyst rating on (BMY) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.
Bristol-Myers Squibb’s strong earnings call and solid valuation metrics are the most significant factors driving the score. Financial performance is robust but tempered by high debt levels. Technical indicators suggest caution with potential bearish momentum.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company primarily focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates in the pharmaceutical industry, with a market focus on therapeutic areas such as oncology, immunology, cardiovascular, and fibrosis.
Average Trading Volume: 14,990,285
Technical Sentiment Signal: Sell
Current Market Cap: $94.97B
See more insights into BMY stock on TipRanks’ Stock Analysis page.